Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. - Wikidata - wikimedia - TriplyDB

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

http://www.wikidata.org/entity/Q33909996

about

Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities Pharmacogenomics of antimicrobial agents.PharmGKB summary: Efavirenz pathway, pharmacokinetics Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.Pharmacogenetic considerations in the treatment of HIV.CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.Frequent malaria illness episodes in two Malawian patients on antiretroviral therapy soon after stopping cotrimoxazole preventive therapy.Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.Variation in CYP2A6 Activity and Personalized Medicine.

P2860

Q26853274-EF434374-0D8D-41B9-B541-F6679AE20048 Q34977413-FC03FB15-EEFC-4FEB-BA69-6DD406DD55E2 Q35706069-69682712-CE75-444A-9B3E-E41A5AEFDEFD Q35910664-FE9603F6-C702-496A-9A66-68BA8814A51D Q35947529-06A99359-D158-4BB2-9ED0-D112101A32A3 Q35974648-0857F464-B2FA-4957-AFFF-B27184A11DDE Q36094233-06993C37-7B56-4E1C-A1EA-BEF89D1CE866 Q36437792-5B6E3093-1911-414F-8712-6D4FF6FB2CF0 Q36801543-FED6B403-CE01-4747-BE3F-C51E256EE5F4 Q36808178-F987FEE8-A365-4A78-93D3-21026B2E4C86 Q37030715-E680C420-ED2C-4B3A-B70D-1F56EA41B8A0 Q37509532-66F7B74F-2032-4AF9-ADA0-C8F05FF3CB70 Q37538760-1F170B2F-C3BD-441A-A6FD-40718B084FA2 Q38782609-3978A678-1C52-44B0-818B-5C57B76BF28C Q38855121-59C4AEA1-5AA3-4ECF-B78D-210A11E212A2 Q38957969-2DB326ED-FA76-4373-BE40-F9DF5C5A302C Q39472422-3DC4CC8D-C9CB-4618-98F1-66E31DD36A01 Q39503882-A2807065-6B1D-465C-BE20-C74E7D1C3A8D Q40190013-E5E3814F-4821-4460-91FC-D3DC318B877F Q41048998-77A5FE3E-6777-4B74-88AB-1F03A0D8F01C Q41995975-549CEB3A-9071-4F83-BCAE-604B6E9BB726 Q47163198-7C704FB7-ACE2-4469-B2D3-A942AC54F16A

P2860

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

http://www.wikidata.org/entity/Q33909996

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Secondary metabolism pathway p ...... B6 slow metabolizer genotypes.

@ast

Secondary metabolism pathway p ...... B6 slow metabolizer genotypes.

@en

type

label

Secondary metabolism pathway p ...... B6 slow metabolizer genotypes.

@ast

Secondary metabolism pathway p ...... B6 slow metabolizer genotypes.

@en

prefLabel

Secondary metabolism pathway p ...... B6 slow metabolizer genotypes.

@ast

Secondary metabolism pathway p ...... B6 slow metabolizer genotypes.

@en

P1433

Q33909996-C138194B-4A51-4B58-92F9-15429C43A6FD

P1476

Q33909996-1F0BFFF1-81FA-42E1-B639-137365EEDB5C

P2093

Q33909996-269202F6-F5EE-4E34-B931-92655DB45D68

Q33909996-37250D7A-82A5-4DBC-9134-4110B6E449AD

Q33909996-62586487-352F-4E35-9B6E-9F685F9AFBED

Q33909996-8B38DB23-5652-4875-B651-68FC3346D7C9

Q33909996-B2571587-2AC9-4B37-AAED-136F29A930AF

Q33909996-BECAF5A7-BD0D-4A60-B490-ABFD7B8AC2B6

Q33909996-C4AC4FA1-7627-4AF8-AAB5-E4602E81957D

Q33909996-D2C801A9-B7E1-429B-A4FD-E158BA98D055

P2860

Q33909996-0B0B0A93-C7A3-4C79-B049-DEFED76B9D64

Q33909996-0F03CB16-9F19-4425-A2ED-1EC118A85F54

Q33909996-10A21CF2-A2CE-4CF2-9296-8B7BC6A29E3A

Q33909996-136846EE-277B-4807-A3DA-969835554812

Q33909996-14450ADD-2B65-4B0B-B146-CC706D64B552

Q33909996-177F9B36-0E57-4FC1-9050-AB35C6F59D99

Q33909996-1C5272A1-2B05-47C5-92F9-30C29F8204DC

Q33909996-201C4A42-D2DA-4EB9-B262-501E80E26371

Q33909996-257FA981-BA33-42EF-BF1A-1C9F9A213A86

Q33909996-30C1ED27-2BD7-4425-8619-38E60658076D

P304

Q33909996-33978C16-AC5C-490B-AAE5-DEB8486E5BF1

P31

Q33909996-11D478D2-3A00-428D-8DA4-03B3141B659B

P356

Q33909996-DF9C4689-2656-4C8D-B589-3D4F6F0F89C7

P407

Q33909996-61D7BD4E-5DDA-4CFB-891C-84B0D21A0645

P433

Q33909996-C4C6753A-FB19-4724-8319-FC9E8FBAB037

P478

Q33909996-6B34CEF3-E142-44FC-B962-D8C955E74B41

P577

Q33909996-3BA76CEC-A1F5-43C2-BF49-4E8C74FF9CD1

P5875

Q33909996-B1EDFD76-FCD5-48F6-B4E2-699BB126C555

P698

Q33909996-1377D2D4-2D40-4382-8B79-A4B1AE578B46

P932

Q33909996-AFB6A530-2E7F-4DDE-AA69-7EF21E9C0D04

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Secondary metabolism pathway p ...... B6 slow metabolizer genotypes.

@en

P2093

Awewura Kwara

http://www.w3.org/2001/XMLSchema#string

Danielle M Richardson

http://www.w3.org/2001/XMLSchema#string

David W Haas

http://www.w3.org/2001/XMLSchema#string

Edward P Acosta

http://www.w3.org/2001/XMLSchema#string

Gene D Morse

http://www.w3.org/2001/XMLSchema#string

Ioannis Papageorgiou

http://www.w3.org/2001/XMLSchema#string

Michael H Court

http://www.w3.org/2001/XMLSchema#string

Paxton Baker

http://www.w3.org/2001/XMLSchema#string

P2860

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation

PLINK: a tool set for whole-genome association and population-based linkage analyses

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502).

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.

P304

2175-2182

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKU110

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261610072

http://www.w3.org/2001/XMLSchema#string

P698

24729586

http://www.w3.org/2001/XMLSchema#string

P932

4100708

http://www.w3.org/2001/XMLSchema#string